Oncopeptalks on the recent FDA decision

In this episode Jakob Lindberg, Chief Scientific Officer discusses the recent decision by the U.S. Food and Drug Administration to reconfirm the withdrawal of Pepaxto in a conversation with David Augustsson, Head of IR and Communication. Topics covered are the journey from U.S. approval to withdrawal for Pepaxto, his view on the recent decision and next, if any, steps in the USA for the drug.